002393 力生制药
已收盘 03-26 15:00:00
资讯
新帖
简况
力生制药(002393)2025年年报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 06:07
力生制药(002393)2025年年报简析:营收净利润同比双双增长,盈利能力上升
天津发展:力生制药年度归母净利润4.16亿元 同比增长125.59%
新浪港股 · 03-25 08:19
天津发展:力生制药年度归母净利润4.16亿元 同比增长125.59%
天津发展控股有限公司 - 力生制药全年总营业收入达13.9亿元人民币
美股速递 · 03-25 06:08
天津发展控股有限公司 - 力生制药全年总营业收入达13.9亿元人民币
图解力生制药年报:第四季度单季净利润同比增长198.13%
证券之星 · 03-25 01:37
图解力生制药年报:第四季度单季净利润同比增长198.13%
力生制药(002393.SZ)发布2025年度业绩,归母净利润4.16亿元,增长125.59%
智通财经 · 03-24 20:19
力生制药(002393.SZ)发布2025年度业绩,归母净利润4.16亿元,增长125.59%
股市必读:力生制药(002393)3月23日收盘跌5.74%,主力净流出1259.88万元
证券之星 · 03-24 02:14
股市必读:力生制药(002393)3月23日收盘跌5.74%,主力净流出1259.88万元
力生制药:公司截止目前不涉及机器人、AI制药、脑机接口相关业务
证券之星 · 03-18
力生制药:公司截止目前不涉及机器人、AI制药、脑机接口相关业务
力生制药:石油涨价对公司药品生产成本无影响
证券之星 · 03-10
力生制药:石油涨价对公司药品生产成本无影响
天津发展:力生制药2025年度归母净利润4.18亿元 同比增长126.72%
智通财经 · 03-10
天津发展:力生制药2025年度归母净利润4.18亿元 同比增长126.72%
力生制药(002393)披露2025年度业绩快报,3月9日股价下跌2.25%
证券之星 · 03-09
力生制药(002393)披露2025年度业绩快报,3月9日股价下跌2.25%
力生制药(002393.SZ)2025年度归母净利润4.18亿元,增长126.72%
智通财经 · 03-09
力生制药(002393.SZ)2025年度归母净利润4.18亿元,增长126.72%
力生制药(002393.SZ)收到伏立康唑片药品注册证
智通财经 · 03-05
力生制药(002393.SZ)收到伏立康唑片药品注册证
力生制药:氨茶碱片(规格
证券之星 · 02-26
力生制药:氨茶碱片(规格
股市必读:力生制药(002393)2月25日董秘有最新回复
证券之星 · 02-26
股市必读:力生制药(002393)2月25日董秘有最新回复
力生制药最新公告:磷酸腺嘌呤原料药通过上市申请
证券之星 · 02-06
力生制药最新公告:磷酸腺嘌呤原料药通过上市申请
力生制药(002393)披露2026年第一次临时股东会决议公告,2月2日股价下跌1.45%
证券之星 · 02-02
力生制药(002393)披露2026年第一次临时股东会决议公告,2月2日股价下跌1.45%
力生制药(002393)披露关于变更持续督导保荐代表人的公告,1月30日股价上涨0.5%
证券之星 · 01-30
力生制药(002393)披露关于变更持续督导保荐代表人的公告,1月30日股价上涨0.5%
力生制药:定期对长期资产进行检视和评估
证券之星 · 01-30
力生制药:定期对长期资产进行检视和评估
股市必读:力生制药(002393)1月27日董秘有最新回复
证券之星 · 01-28
股市必读:力生制药(002393)1月27日董秘有最新回复
力生制药(002393)披露部分限制性股票回购注销完成暨股份变动公告,1月27日股价下跌1.82%
证券之星 · 01-27
力生制药(002393)披露部分限制性股票回购注销完成暨股份变动公告,1月27日股价下跌1.82%
加载更多
公司概况
公司名称:
天津力生制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-04-23
主营业务:
天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山®吲达帕胺片、三鱼®氨酚咖匹林片、希福尼®头孢地尼分散片、友好®麻仁软胶囊、生化®氢化可的松琥铂酸钠冻干粉针和碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。公司坚持以科技创新赋能产业高质量发展,创新能力和可持续发展能力持续增强,产品包括心脑血管、消化、抗感染、呼吸、跌打等15大类297个药品,拥有注册商标189个。
发行价格:
45.00
{"stockData":{"symbol":"002393","market":"SZ","secType":"STK","nameCN":"力生制药","latestPrice":23.43,"timestamp":1774508619000,"preClose":23.23,"halted":0,"volume":9143243,"delay":0,"changeRate":0.0086,"floatShares":250000000,"shares":258000000,"eps":2.5159,"marketStatus":"已收盘","change":0.2,"latestTime":"03-26 15:00:00","open":23.69,"high":23.8,"low":23.37,"amount":215000000,"amplitude":0.0185,"askPrice":23.43,"askSize":48,"bidPrice":23.42,"bidSize":43,"shortable":0,"etf":0,"ttmEps":2.5159,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":5,"adr":0,"adjPreClose":23.23,"symbolType":"stock","openAndCloseTimeList":[[1774488600000,1774495800000],[1774501200000,1774508400000]],"highLimit":25.55,"lowLimit":20.91,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":257586843,"isCdr":false,"pbRate":1.29,"roa":"--","peRate":9.312771,"roe":"8.47%","epsLYR":1.62,"committee":-0.650206,"marketValue":6035000000,"turnoverRate":0.0365,"status":0,"floatMarketCap":5864000000},"requestUrl":"/m/hq/s/002393","defaultTab":"news","newsList":[{"id":"2622000421","title":"力生制药(002393)2025年年报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000421","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622000421?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:07","pubTimestamp":1774476437,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期力生制药发布2025年年报。截至本报告期末,公司营业总收入13.92亿元,同比上升4.18%,归母净利润4.16亿元,同比上升125.59%。本报告期力生制药盈利能力上升,毛利率同比增幅0.35%,净利率同比增幅118.2%。该数据高于大多数分析师的预期,此前分析师普遍预期2025年净利润为盈利4.11亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600006119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"gpt_icon":0},{"id":"2622128540","title":"天津发展:力生制药年度归母净利润4.16亿元 同比增长125.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622128540","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622128540?lang=zh_cn&edition=full","pubTime":"2026-03-25 08:19","pubTimestamp":1774397940,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 天津发展(00882)发布力生制药(002393.SZ)截至2025年12月31日止年度业绩,该公司营业收入为13.92亿元,同比增长4.18%。归属于上市公司股东的净利润为4.16亿元,同比增长125.59%。基本每股收益为1.62元。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-25/doc-inhsecsh3726855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00882","002393"],"gpt_icon":0},{"id":"1190843722","title":"天津发展控股有限公司 - 力生制药全年总营业收入达13.9亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1190843722","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190843722?lang=zh_cn&edition=full","pubTime":"2026-03-25 06:08","pubTimestamp":1774390094,"startTime":"0","endTime":"0","summary":"天津发展控股有限公司近日披露,其旗下核心医药板块——力生制药在上一财年实现总营业收入13.9亿元人民币。这一业绩凸显了公司在医药制造领域的稳健表现和市场竞争力。力生制药作为天津发展的重要子公司,其业务进展对集团整体战略布局具有关键影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","002393","BK0239","BK1232","BK0188","00882"],"gpt_icon":0},{"id":"2622092372","title":"图解力生制药年报:第四季度单季净利润同比增长198.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622092372","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622092372?lang=zh_cn&edition=full","pubTime":"2026-03-25 01:37","pubTimestamp":1774373854,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药2025年年报显示,当年度公司主营收入13.92亿元,同比上升4.18%;归母净利润4.16亿元,同比上升125.59%;扣非净利润1.69亿元,同比上升63.62%;其中2025年第四季度,公司单季度主营收入3.85亿元,同比上升23.16%;单季度归母净利润4554.3万元,同比上升198.13%;单季度扣非净利润4179.91万元,同比上升1363.13%;负债率16.54%,投资收益3.25亿元,财务费用-4863.99万元,毛利率55.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500003169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"gpt_icon":0},{"id":"2621064024","title":"力生制药(002393.SZ)发布2025年度业绩,归母净利润4.16亿元,增长125.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064024","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621064024?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:19","pubTimestamp":1774354790,"startTime":"0","endTime":"0","summary":"智通财经APP讯,力生制药 发布2025年年度报告,该公司营业收入为13.92亿元,同比增长4.18%。归属于上市公司股东的净利润为4.16亿元,同比增长125.59%。基本每股收益为1.62元。此外,拟向全体股东每10股派发现金红利6元(含税),送红股0股(含税),以资本公积金向全体股东每10股转增2股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"力生制药(002393.SZ)发布2025年度业绩,归母净利润4.16亿元,增长125.59%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002393"],"gpt_icon":0},{"id":"2621085259","title":"股市必读:力生制药(002393)3月23日收盘跌5.74%,主力净流出1259.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621085259","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621085259?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:14","pubTimestamp":1774289653,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘,力生制药报收于20.54元,下跌5.74%,换手率2.93%,成交量7.33万手,成交额1.52亿元。当日关注点来自交易信息汇总:力生制药3月23日收盘报20.54元,跌5.74%,已连续3日下跌。前10个交易日中,主力资金累计净流出819.6万元,股价累计下跌5.45%;融资余额累计减少396.95万元,融券余量累计减少300股。3月23日资金流向显示:主力资金净流出1259.88万元,游资资金净流入414.99万元,散户资金净流入844.89万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400002037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","002393"],"gpt_icon":0},{"id":"2620565372","title":"力生制药:公司截止目前不涉及机器人、AI制药、脑机接口相关业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2620565372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620565372?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:52","pubTimestamp":1773838339,"startTime":"0","endTime":"0","summary":"请问公司在AI制药、脑机接口等前沿领域的合作,是否有最新进展?公司主营业务聚焦于现有医药相关领域,严格按照监管要求开展经营,相关业务范围未发生重大变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800038810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","01477","BK0188","BK0239","BK1574","002393","BK1191"],"gpt_icon":0},{"id":"2618260055","title":"力生制药:石油涨价对公司药品生产成本无影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2618260055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618260055?lang=zh_cn&edition=full","pubTime":"2026-03-10 11:37","pubTimestamp":1773113824,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药(002393)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问:你好董秘,请问石油涨价,对贵司的药品生产成本影响大吗?力生制药回复:投资者您好,石油涨价对公司药品生产成本无影响,感谢关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000014978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","002393"],"gpt_icon":0},{"id":"2618960898","title":"天津发展:力生制药2025年度归母净利润4.18亿元 同比增长126.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618960898","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618960898?lang=zh_cn&edition=full","pubTime":"2026-03-10 06:44","pubTimestamp":1773096240,"startTime":"0","endTime":"0","summary":"天津发展(00882)发布力生制药(002393.SZ)2025年度业绩快报,该公司取得营业总收入13.93亿元,同比增长4.23%;利润总额4.56亿元,同比增长111.36%;归母净利润4.18亿元,同比增长126.72%;基本 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260310/c675173512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002393"],"gpt_icon":0},{"id":"2618550627","title":"力生制药(002393)披露2025年度业绩快报,3月9日股价下跌2.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618550627","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618550627?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:49","pubTimestamp":1773067753,"startTime":"0","endTime":"0","summary":"截至2026年3月9日收盘,力生制药报收于21.7元,较前一交易日下跌2.25%,最新总市值为55.9亿元。该股当日开盘22.01元,最高22.19元,最低21.6元,成交额达1.12亿元,换手率为2.05%。近日,天津力生制药股份有限公司披露2025年度业绩快报。公告显示,公司2025年营业总收入为1,392,663,934.63元,同比增长4.23%;营业利润为469,957,828.86元,同比增长112.03%;利润总额为456,432,176.66元,同比增长111.36%;归属于上市公司股东的净利润为418,365,973.76元,同比增长126.72%。扣除非经常性损益后的净利润为169,084,905.34元,同比增长64.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900035614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002393","BK0188"],"gpt_icon":0},{"id":"2618264204","title":"力生制药(002393.SZ)2025年度归母净利润4.18亿元,增长126.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618264204","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618264204?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:17","pubTimestamp":1773051458,"startTime":"0","endTime":"0","summary":"智通财经APP讯,力生制药(002393.SZ)披露2025年度业绩快报,公司2025年度实现营业总收入13.93亿元,比上年同期增加4.23%。归属于上市公司股东的净利润4.18亿元,同比增长126.72%。基本每股收益1.62元。报告期公司积极开拓市场,扩大产品销量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"力生制药(002393.SZ)2025年度归母净利润4.18亿元,增长126.72%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002393"],"gpt_icon":0},{"id":"2617883511","title":"力生制药(002393.SZ)收到伏立康唑片药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2617883511","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617883511?lang=zh_cn&edition=full","pubTime":"2026-03-05 15:47","pubTimestamp":1772696873,"startTime":"0","endTime":"0","summary":"智通财经APP讯,力生制药(002393.SZ)公告,公司收到国家药品监督管理局颁发的关于伏立康唑片0.2g规格的《药品注册证书》和伏立康唑片50mg规格的《药品注册证书》,上述药品通过药品上市许可申请。伏立康唑片是一种广谱的三唑类抗真菌药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"力生制药(002393.SZ)收到伏立康唑片药品注册证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","002393","BK0028","BK0239"],"gpt_icon":0},{"id":"2614904110","title":"力生制药:氨茶碱片(规格","url":"https://stock-news.laohu8.com/highlight/detail?id=2614904110","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614904110?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:52","pubTimestamp":1772110346,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药02月26日在投资者关系平台上答复投资者关心的问题。谢谢力生制药回复:尊敬的投资者您好,公司在仿制药方面,公司持续推进仿制药一致性评价工作,取得了显著成果。2026年1月,公司申报的氨茶碱片仿制药一致性评价补充申请获国家药品监督管理局正式批准,进一步丰富了公司呼吸系统领域的产品矩阵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600035398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002393","BK0188","BK0239"],"gpt_icon":0},{"id":"2614037627","title":"股市必读:力生制药(002393)2月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2614037627","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614037627?lang=zh_cn&edition=full","pubTime":"2026-02-26 01:52","pubTimestamp":1772041931,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘,力生制药报收于21.76元,上涨0.18%,换手率0.86%,成交量2.15万手,成交额4683.23万元。董秘最新回复投资者: 好酒不怕巷子深,希望新的一年,在新管理层得领导下,积极发扬自力更生,做好人,做好药的力生精神,让更多媒体及投资机构看到力生的国企担当!当日关注点来自交易信息汇总:2月25日主力资金净流出270.65万元,显示主力短期看空情绪明显。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600001005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002393","BK0188","BK0028"],"gpt_icon":0},{"id":"2609156578","title":"力生制药最新公告:磷酸腺嘌呤原料药通过上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2609156578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609156578?lang=zh_cn&edition=full","pubTime":"2026-02-06 17:02","pubTimestamp":1770368539,"startTime":"0","endTime":"0","summary":"力生制药(002393.SZ)公告称,公司收到国家药品监督管理局颁发的关于磷酸腺嘌呤原料药《化学原料药上市申请批准通知书》,该品种通过化学原料药上市申请。磷酸腺嘌呤为核酸和辅酶的组成成分,参与体内DNA和RNA的合成,临床上用于防治各种原因引起的白细胞减少症。公司该品种通过化学原料药上市申请,有利于与公司制剂产品形成产业协同,提升市场竞争力。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600027857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002393","BK0239"],"gpt_icon":0},{"id":"2608386017","title":"力生制药(002393)披露2026年第一次临时股东会决议公告,2月2日股价下跌1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608386017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608386017?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:49","pubTimestamp":1770043758,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘,力生制药报收于21.68元,较前一交易日下跌1.45%,最新总市值为55.84亿元。该股当日开盘22.22元,最高22.37元,最低21.68元,成交额达6145.03万元,换手率为1.11%。近日,天津力生制药股份有限公司发布《2026年第一次临时股东会决议公告》。各项提案均获高比例同意通过,出席股东代表有表决权股份总数的54.7512%。律师见证本次会议召集、召开程序合法,表决结果有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002393","BK0239","BK0028"],"gpt_icon":0},{"id":"2607042033","title":"力生制药(002393)披露关于变更持续督导保荐代表人的公告,1月30日股价上涨0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607042033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607042033?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:34","pubTimestamp":1769787256,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,力生制药报收于22.0元,较前一交易日上涨0.5%,最新总市值为56.67亿元。该股当日开盘21.79元,最高22.33元,最低21.79元,成交额达9268.85万元,换手率为1.68%。力生制药近日披露《关于变更持续督导保荐代表人的公告》。公告显示,公司于近日收到渤海证券出具的《关于变更力生制药 IPO项目持续督导保荐代表人的通知》。因原保荐代表人张运发先生退休,渤海证券指派张化先生接替其持续督导工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","002393"],"gpt_icon":0},{"id":"2607064028","title":"力生制药:定期对长期资产进行检视和评估","url":"https://stock-news.laohu8.com/highlight/detail?id=2607064028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607064028?lang=zh_cn&edition=full","pubTime":"2026-01-30 11:33","pubTimestamp":1769743990,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药01月30日在投资者关系平台上答复投资者关心的问题。未来,我们将继续根据市场环境、技术迭代及产品结构变化,定期对长期资产进行检视和评估,对因技术落后、经济绩效不达预期或闲置的产能与资产,及时进行减值测试并计提相应的减值准备,以更真实、公允地反映公司的资产状况和经营成果,切实维护全体股东的利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000016555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2606673485","title":"股市必读:力生制药(002393)1月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606673485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606673485?lang=zh_cn&edition=full","pubTime":"2026-01-28 01:58","pubTimestamp":1769536693,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘,力生制药报收于22.7元,下跌1.82%,换手率2.16%,成交量5.41万手,成交额1.22亿元。来自公司公告汇总:力生制药完成对1名离职激励对象所持30,016股限制性股票的回购注销,总股本相应减少。本次回购注销完成后,公司总股本由257,616,859股减少至257,586,843股,有限售条件的境内自然人持股相应减少30,016股。相关手续已于2026年1月27日在中国证券登记结算有限责任公司深圳分公司办理完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800001178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002393","BK0239"],"gpt_icon":0},{"id":"2606863738","title":"力生制药(002393)披露部分限制性股票回购注销完成暨股份变动公告,1月27日股价下跌1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606863738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606863738?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:30","pubTimestamp":1769524231,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘,力生制药报收于22.7元,较前一交易日下跌1.82%,最新总市值为58.47亿元。该股当日开盘23.08元,最高23.08元,最低22.35元,成交额达1.22亿元,换手率为2.16%。近日,天津力生制药股份有限公司发布《关于部分限制性股票回购注销完成暨股份变动的公告》。本次回购注销完成后,公司总股本由257,616,859股减少至257,586,843股,有限售条件的境内自然人持股相应减少30,016股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700041997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","002393"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774539164975,"stockEarnings":[{"period":"1week","weight":-0.003},{"period":"1month","weight":0.085},{"period":"3month","weight":0.1123},{"period":"6month","weight":0.0378},{"period":"1year","weight":0.4075},{"period":"ytd","weight":0.0847}],"compareEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.0271},{"period":"1year","weight":0.1667},{"period":"ytd","weight":-0.0093}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"天津力生制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21774人(较上一季度减少3.69%)","perCapita":"11495股","listingDate":"2010-04-23","address":"天津市西青区西青经济技术开发区赛达北一道16号","registeredCapital":"25758万元","survey":" 天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山®吲达帕胺片、三鱼®氨酚咖匹林片、希福尼®头孢地尼分散片、友好®麻仁软胶囊、生化®氢化可的松琥铂酸钠冻干粉针和碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。公司坚持以科技创新赋能产业高质量发展,创新能力和可持续发展能力持续增强,产品包括心脑血管、消化、抗感染、呼吸、跌打等15大类297个药品,拥有注册商标189个。","listedPrice":45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"力生制药,002393,力生制药股票,力生制药股票老虎,力生制药股票老虎国际,力生制药行情,力生制药股票行情,力生制药股价,力生制药股市,力生制药股票价格,力生制药股票交易,力生制药股票购买,力生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}